Huawei will build the industry’s first digital robot with China’s national pharmaceutical group Sinopharm for the pharmaceutical industry. This is a brand new advancement made by the Chinese tech maker to advance its growth in digital robot technologies.
In 2019, Sinopharm began to explore digital robot technology. Several subsidiaries have implemented more than 200 business processes. There are issues such as scattered business scenarios, inability to share robotic resources, and inconsistent business processes. In order to solve some problems in the first tests, open up resource sharing, unify and optimize business processes, and realize the digitization of deep integration of operations and businesses.
In 2022, Sinopharm teamed up with Huawei’s digital robot team and Huawei’s partners. This partnership focuses on key points such as customers, data and business elements, sorted out the business process, and planned and built the first digital robot competence center platform in the domestic pharmaceutical industry.
Relying on the large-scale application capabilities of Huawei’s WeAutomate digital robots and the capabilities of mature products, Sinopharm has built a digital robot capability center platform that can meet automation application needs. thousands of group subsidiaries.
After the launch, all subsidiaries of Sinopharm Holdings can share common technology in business processes and share digital robot resources in a unified and intensive manner. In addition, the Sinopharm Digital Robotics Competence Center can fully support common situations of the group and customized scenarios of subsidiaries.
The common scene process is built uniformly by the head office and can be used by all subsidiaries. On the other hand, the custom scene process is customized and shared by the affiliates.
In the future, Huawei’s WeAutomate digital robot will continue to provide technological advantages and help Sinopharm promote broader digital robot scenarios to all sub-enterprises. On the basis of realizing the sharing of digital robot resources, it will simultaneously leverage the innovation capabilities of branch enterprises to meet the needs of enterprises.
The process of implementing Huawei’s digital robots is also a process of normalizing and standardizing the general scenarios of subsidiaries, which promotes the optimization and unification of Sinopharm’s business processes. After the launch of Sinopharm Digital Robotics Competence Center, the efficiency of online robot business scenarios can be increased up to 25 times, and the average efficiency can be increased by more than 10 times, effectively unleashing digital momentum.
Sinopharm Holdings Co., Ltd. was established in Shanghai in January 2003 and listed in Hong Kong in September 2009. It comprises two A-listed companies, Sinopharm Group Pharmaceutical Co., Ltd. and Sinopharm Accord Pharmaceutical Co., Ltd., with a total of more than one thousand subsidiaries.
Today, it has become one of the leading distributors and retailers of pharmaceuticals, healthcare products and medical devices in China, as well as a leading provider of supply chain services. Sinopharm ranks 22nd among Fortune China’s Top 500 in 2021.
